

PCT

F064

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/19, 35/36, C08L 89/06	A1	(11) International Publication Number: WO 99/65470 (43) International Publication Date: 23 December 1999 (23.12.99)
<p>(21) International Application Number: PCT/US99/13861</p> <p>(22) International Filing Date: 18 June 1999 (18.06.99)</p> <p>(30) Priority Data: 60/089,865 19 June 1998 (19.06.98) US</p> <p>(71) Applicant (for all designated States except US): LIFECCELL CORPORATION [US/US]; 3606 Research Forest Drive, The Woodlands, TX 77381 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GRIFFEY, Edward, S. [US/US]; 5 Gannet Hollow Place, The Woodlands, TX 77381 (US). LIVESEY, Stephen, A. [AU/AU]; 104 Napoleon Street, Eltham, VIC 3095 (AU). SCHIFF, Charles, M. [US/US]; 117 North Floral Leaf Circle, The Woodlands, TX 77381 (US). BOERBOOM, Lawrence, E. [US/US]; 333 Holly Creek Court #1605, The Woodlands, TX 77381 (US).</p> <p>(74) Agents: WHITE, Carter, J. et al.; Arnold White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: PARTICULATE ACELLULAR TISSUE MATRIX</p> <p>(57) Abstract</p> <p>A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles of desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

PARTICULATE ACELLULAR TISSUE MATRIX

The present invention claims priority of U.S. Provisional Patent Application No.: 60/089,865; Filed 19 June 1998.

BACKGROUND OF THE INVENTION

5 Human, animal and synthetic materials are currently used in medical procedures to augment tissue or repair or correct tissue defects. To be optimum, such materials should not migrate and should promote the regeneration of normal tissue, repopulating with the host's cells, revascularizing, and integrating with the patient's own tissue without triggering an inflammatory response that results in the degradation or resorption of the material. Additionally, the manner of
10 delivery of such material, e.g. by surgical procedure or by injection, may significantly affect the clinical applications of the material, the ease of use by the physician and the cost of the procedure.

Injectable collagen and other materials have been used clinically for a wide variety of pathological and cosmetic applications in the fields of reconstructive surgery, dermatology,
15 oncology, otolaryngology and urology. Currently, the most widely used form of injectable collagen is derived from crosslinked bovine Type I collagen. In human clinical applications the effect of this xenogenic transplant is resorption by the human host. Patients receiving these xenogenic grafts are susceptible to an immune response to the animal collagen, requiring prescreening for existing antibodies. Examples of such materials may be found in U.S. Patent
20 Numbered: 4,582,640; 5,104,957; 5,728,752; and 5,739,176.

Human collagen that may be injected is currently available and sold under the tradenames Autologen® and Dermologen® and is manufactured by Collagenesis. This material is typically derived from autologous collagen obtained during elective surgery or allogenic collagen from cadavers. The starting material is dissociated by mechanical means and
25 chemically treated to remove all noncollagenous proteins. The collagen is treated with additional chemicals to mask or crosslink the adverse effects of these damaged and exposed collagen fibers. More information with regard to this technology may be found in U.S. Patent Numbers: 4,969,912 and 5,332,802.

AlloDerm®, produced by LifeCell Corporation, is an acellular tissue matrix which is
30 produced from normal human skin using processing techniques established to remove the

- 2 -

epidermis and cells within the dermis without significantly altering the normal biochemistry and molecular architecture of the connective tissue matrix. The resulting product is in a freeze-dried form allowing extended shelf life and ease of shipping without degradation or loss of the normal tissue matrix components. AlloDerm® is used clinically to repair or replace damaged or inadequate tissues. Reported applications for AlloDerm® include: full thickness burn injury, replacement of lost gingiva due to periodontal disease, reconstructive surgical applications involving the replacement of lost tissue or restoration of normal surface contours of skin damaged due to injury or aging neurosurgical application to replace lost dura and in urological applications such as bladder slings and pelvic floor reconstruction.. AlloDerm® has been reported to integrate at the graft site where it is rapidly repopulated with the normal milieu of host cells. A reported benefit of AlloDerm® is that it maintains the structure and biochemistry of the tissue matrix, promoting normal tissue regeneration. Studies have indicated that AlloDerm® retains decorin, hyaluronic acid, chondroitin sulfates, nidogen, growth factors and other biochemical proteins present in normal soft tissues. Additionally, AlloDerm® is reported to contain the basement membranes of vascular channels and the orientation of elastin and collagen fibers of the starting dermal tissue. For these reasons it is believed that the structure and biochemistry of the AlloDerm® matrix promotes tissue regeneration. Reducing sheet AlloDerm® to a particulate suitable for injection should extend the beneficial properties of AlloDerm® to several new applications.

Methods presently used to produce currently available injectable collagen materials include mechanical disruption of the starting material in its wet, hydrated state. However, when such processes are carried out on intact autograft, allograft or xenograft tissue, damage to the matrix occurs such that following transplantation a foreign body response and rapid resorption of the tissue matrix occurs. Further, microscopic and histological analysis of material processed in such a manner exhibit mechanical disruption of the collagen fibers. Mechanical disruption of dried human or animal tissue at non-cryogenic temperatures is believed to create a similar disruption of the collagen fibers, resulting in a foreign body response by the recipient and resorption of the material.

Thus there exists an unmet need for a method of making an intact particulate acellular tissue matrix from acellular tissues.

- 3 -

SUMMARY OF THE INVENTION

The present invention is generally directed to a method of processing an acellular tissue matrix to give a particulate acellular tissue matrix. A general embodiment of the method of the present invention includes the steps of: cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; and separating the resulting particles by size at cryogenic temperatures. In a preferred embodiment, the method of the present invention includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use.

It is generally preferred that the cryofracturing be carried out at temperatures below 0° C and preferably the temperature should be below about -50 °C and more preferably should be below about -100° C. Commercially available refrigerants can be used to achieve such temperatures, which may include halocarbon refrigerants, liquid carbon dioxide, liquid nitrogen, liquid argon, liquid helium and other similar such well known non-chemically reactive and thus inert and non-toxic refrigerants. The separation of the resulting particles should also be carried out at cryogenic temperatures utilizing a series of metal mesh screens suitably sized for the particle range desired. In one preferred embodiment the screens are selected so as to isolate particles having a size of about 1 micron to about 900 microns and preferably screens are selected to isolate particles having a size from about 30 microns to about 800 microns. The present invention also encompasses the product of the above described processes.

These and other features of the present invention are more fully set forth in the following description of illustrative embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The description is presented with reference to the accompanying drawings in which:

FIG. 1 is an illustration of a bundle of collagen fibers which have been cryofractured in accordance with the present invention.

- 4 -

FIG. 2 is an illustration of a bundle of collagen fibers which have been homogenized at room temperature.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

5 Acellular tissue matrix tissue is the result of a multistep process in which the tissue is collected from a donor and processed so as to isolate the natural tissue matrix. In its preferred form, the process includes the steps of processing biological tissues including treatment with a stabilizing solution to reduce procurement damage, treatment with a processing solution to remove cells and other antigenic tissue components, treatment with a cryoprotectant solution, 10 freezing and storage under specific conditions to avoid functionally significant damaging ice crystal formation, drying under conditions to prevent damaging ice recrystallization, storage in the dry state at above freezing temperatures, rehydration under specific conditions and with a rehydration solution to minimize surface tension damage and further augment the selective preservation of the matrix, and reconstitution with viable cells that will not be rejected by the 15 host.

The above summarized process for producing acellular dermal or other tissue matrix is more fully disclosed in U.S. Patent Number 5,336,616, the entire contents of which is incorporated herein by reference.

20 One of skill in the art will appreciate however that other acellular tissue matrix tissues may be used in the present invention. For example, acellular tissue matrix tissue derived from xenogenic source may be used in addition to the human derived tissue disclosed above, and other tissues such as blood vessels, heart valves, fascia and nerve connective tissue may be used to create a particulate acellular matrix within the scope of the present invention. Thus in one preferred embodiment of the present invention, the method disclosed herein utilizes acellular 25 tissue matrix tissue, herein also referred to as AlloDerm®, which is commercially available from LifeCell Corporation, The Woodlands Texas.

30 The process of the present invention utilizes a chemical free and minimally disruptive technique which minimizes the damage to the collagen fibers including sheared fiber ends that result from the conventional wet or dry processes previously disclosed. The resulting particulate acellular tissue matrix can be suspended in a suitable carrying agent and thereby is made suitable

- 5 -

for delivery through hypodermic needle injection or other modes of application including, spraying, layering, packing, in-casing or combinations of these methods. One of skill in the art should also appreciate that the particulate acellular matrix may be reconstituted into a sheet, or into a gelatinous form or other forms for use.

5 Generally the method of the present invention includes the steps of: cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; and separating the resulting particles by size at cryogenic temperatures. In a preferred embodiment, the method of the present invention includes: cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze
10 drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. In a more preferred embodiment the method of the present invention includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; freeze drying the fraction of particles
15 desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix; and rehydrating the dry particulate acellular tissue matrix.

Preferably the dry acellular tissue matrix is cryogenically cooled to a temperature that permits the cryogenic fracturing, shattering or milling of the material. In one embodiment of the present invention a sterilized homogenizer cooled to liquid nitrogen temperatures is utilized.
20 The resulting cryogenically fractured material is then passed through a series of particle size exclusion screens so as to isolate the desired range of particulate acellular tissue matrix material. Once isolated, the particulate acellular tissue matrix material may be freeze-dried so as to remove any moisture that may have been absorbed to the matrix during the above described process.

25 Generally the particulate acellular tissue matrix is produced in such a way as to minimize the amount of mechanical damage incurred when reducing an intact tissue to a particulate form. As illustrated in Fig. 1, the cryofracturing of the collagen fibers in accordance with the present invention results in a "clean" break of the collagen fibers. This is in contrast with the frayed ends and substantially damaged collagen fibers that result from the room temperature shredding
30 of collagen tissue as is the practice in the prior art. The damage cause by the mechanical

- 6 -

shredding of the collagen fiber bundle, and in particular the end of the collagen fibers is illustrated in Fig. 2. The above illustrations are based on electron microscopic observation of the processed materials and are representative of the ends of the collagen fiber bundles present in the collagen based tissues.

5 In developing the process of the present invention, several factors were found to be important to the new and unexpected properties of the resulting particulate acellular tissue matrix. One such factor is the temperature at which the homogenization or cryofracturing of the dry acellular matrix, such as AlloDerm®, takes place. As the term is used herein, homogenization and cryofracturing are utilized interchangeably and are intended to mean the
10 process of creating particulate material from the sheet like starting material. It has been found that the temperature at which the cryofracturing takes place should be sufficiently enough below room temperature so that the collagen fibers are cryogenically fractured and not shredded or torn. Generally the temperature should be below 0° C and preferably the temperature should be below about -50 °C and more preferably should be below about -100° C. Commercially available
15 refrigerants can be used to achieve such temperatures, which may include halocarbon refrigerants, liquid carbon dioxide, liquid nitrogen, liquid argon, liquid helium and other similar such well known non-chemically reactive and thus inert and non-toxic refrigerants.

Another factor found to be important in achieving the present invention is the particle size of the particulate acellular tissue matrix material. In order to select the desired range of
20 particles, a cryogenically cooled homogenizing tower is utilized. The role of the homogenization tower is to separate particles which are too small or too large in size from those within the desired particle size range. In one embodiment, liquid nitrogen is utilized in combination with a first metal screen to reject those particles that are too large. A second metal screen is used in conjunction with liquid nitrogen to capture those particles of the proper
25 minimum size and to allow those particles that are too small to be removed. In one preferred embodiment the first screen is about 0.03 inch (0.0762 cm) metal screen and the second screen is about 0.0015 inch (0.00381 cm) metal screen. In another embodiment the screens are selected so as to isolate particles having a size of about 1 microns to about 900 microns and preferably screens are selected to isolate particles having a size from about 30 microns to about 800
30 microns.

- 7 -

The resulting particulate acellular tissue matrix may be rehydrated by suspension of the particles in any suitable aqueous solution, preferably normal saline and local anesthetic. If desired the rehydrated particulate acellular tissue matrix may be isolated by filtration or pelletizing the particle via centrifugation and decantation of the supernatant. The particulate acellular tissue matrix may then be resuspended to an appropriate concentration in a suitable physiologically compatible carrier, such as normal saline, normal saline and local anesthetic or if desired a pharmaceutical carrier. Either the physiological carrier or the rehydrating saline solution may contain antibiotics or other drugs, cells or cell extracts, anti-inflammatory agents, proteoglycans, analgesics, hemostatic agents, growth factors such as epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogenic proteins, chondrocyte growth factor and other similar such components as well as other components that are desirable at the injection site.

Once rehydrated, the particulate acellular tissue matrix may also be combined with stem or progenitor cells prior to or during transplantation into the host. These stem cells may be native to the site of transplantation, but due to their nature need not be. One of ordinary skill in the art should understand and appreciate that upon division, stem cells replicate and also give rise to cells that differentiate further into one or more specialized cells. Such stem cells may include mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells, and other similar cells.

Thus in one illustrative embodiment of the present invention the processing of acellular tissue matrix to create injectable size particles includes: cutting sheets of dry acellular tissue matrix into strips using a modified cutting or meshing devise; homogenization of the dry acellular tissue matrix strips at cryogenic temperatures; separation of the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired to remove any moisture that may have been absorbed during homogenizing.

Another illustrative embodiment of the present invention includes the processing of acellular tissue derived from a human donor, e.g. AlloDerm®, to create injectable size particles includes: cutting sheets of dry acellular tissue matrix into strips using a modified cutting or meshing devise; equilibration of homogenizing equipment to liquid nitrogen temperatures;

- 8 -

addition of dry acellular tissue matrix strips to a liquid nitrogen cooled homogenizer; cryofracturing of the dry acellular tissue matrix strips at liquid nitrogen temperatures; separation of the resulting particles by size at liquid nitrogen temperatures; and freeze drying the fraction of particles desired to remove any moisture that may have been absorbed during homogenizing.

5 Potential applications of the particulate acellular tissue matrix materials disclosed herein may include: dermatological applications such as acne scar revision, replacement of dermis lost to disease or accident; urological applications such as the relief of incontinence, and vesicoureteral reflux; otolaryngological applications including vocal cord position adjustment; reconstructive surgical applications to replace tissue lost to cancer surgery or other surgical
10 procedures in which there is the removal of tissue; cosmetic surgery procedures such as tissue replacement, reconstruction or augmentation procedures; correctional procedures for gastrointestinal reflux; and other applications which should be appreciated by one of skill in the art. As an illustrative example, see U.S. Patent No. 5,712,252, the contents of which are hereby incorporated herein by reference and the references cited therein.

15 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate
20 that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the scope of the invention.

Preparation Of Acellular Tissue Matrix

The following procedure was carried out in accordance with the teachings of process for producing acellular dermal or other tissue matrix is fully disclosed in U.S. Patent Number
25 5,336,616, the entire contents of which is incorporated herein by reference, as well as being the subject of co-pending U.S. Patent Applications including: 09/029,179, filed August 22, 1998; and the contents of which are hereby incorporated herein by reference. This material is commercially available from LifeCell Corporation, The Woodlands Texas.

30 Donor skin is harvested under aseptic conditions with a dermatome, and maintained at 4°C in RPMI 1640 tissue culture media containing penicillin and streptomycin solution for no

- 9 -

more than 7 days prior to further processing. Transportation to LifeCell's tissue processing center is via overnight delivery, on wet ice, in the same media. On arrival at the processing center, the temperature of the tissue container is verified to be at least 4°C, or the skin discarded. Following verification of container temperature, donor identification and test screening data, the skin is transferred to a laminar-flow hood for further processing.

The donor skin is removed from the transportation container and placed with its reticular side down on a piece of sizing support being a low density polyethylene. An appropriately sized piece of gauze is added to the epidermal side of the skin which is then cut into a rectangular piece as large as possible, not to exceed a 4 x 4 inch square and no smaller than 2 x 3 inches. The skin is then placed reticular side down, in a petri dish, to which 50 ml of De-epidermizing Solution consisting of 1M NaCl is added. The petri dish is then transferred to an incubator and incubated at 37°±2°C for 18 to 32 hours for human skin and 35 to 55 hours for porcine skin.

After incubation, the petri dish containing the skin is transferred to a laminar flow hood for deepidermization. The gauze is first removed and discarded. The epidermis is then gently grasped with forceps and pulled away from dermis as a sheet. The excess De-epidermizing Solution is then aspirated. A slit approximately one centimeter long is then made in the lower left corner of the dermis to identify the upper and lower surfaces.

The dermis is next rinsed in the same petri dish by the addition of 50 ml Tissue Wash Solution, consisting of sterile Hanks' balanced salt solution. The petri dish is then placed on a rotator at 40±5 RPM for 5 minutes at room temperature (20°-26°C). The petri dish is then returned to the laminar flow hood and the lid from the petri dish is removed in order to aspirate the Tissue Wash Solution. This procedure is repeated a further two times.

The dermis is then treated with 50 ml. of De-cellularizing solution and the petri dish is placed on a rotator at 40±5 RPM for 1 hour at room temperature (20°-26°C). The decellularizing solution for human skin consists of 0.5% sodium dodecyl sulfate in Hanks' balanced salt solution and for porcine skin contains 1 mM disodium ethylenediamine tetraacetic acid (EDTA). The De-cellularizing solution is removed by aspiration. The dermis is then washed with 50 ml of Tissue Wash Solution. The petri dish is then placed on a rotator at 40±5 RPM for 5 minutes at room temperature (20°-26°C). The Tissue Wash Solution is removed by aspiration. The washing procedure is repeated (2) times. After the dermis has been washed a total of 3 times 50

- 10 -

ml of Pre-freezing Solution is added to the petri dish. The dish is then placed on a rotator at 40±5 RPM for 30 minutes at room temperature (20°-26°C). The prefreezing solution for human skin consists of 7% dextran (70,000 MWT), 6% sucrose, 6% raffinose and 1 mM disodium ethylenediamine tetraacetic acid in Hanks' balanced salt solution. The prefreezing solution for porcine skin consists of 7.5% dextran (70,000 MWT), 6% sucrose, 7.5% polyvinylpyrrolidone (MWT 40,000), 1.25% raffinose and 1 mM disodium ethylenediamine tetraacetic acid made up in Hanks' balanced salt solution.

A new piece of gauze is then placed on the papillary side of the dermis and the dermis is turned over so that the reticular side faces up. The backing from the reticular side of the piece of dermis is discarded into a biohazard waste container. An approximately 0.5 to 1.0 cm wide strip of backing and dermis is then cut from the original sample. This strip is then cut into two satellite pieces, each approximately 1.0 cm long. All necessary quality assurance is ultimately performed on these satellite samples, including microbiology and structural analysis.

The tissues are then transferred into individual TYVEK bags. The tissues are positioned in the bag backing side up with the white vent side down. The TYVEK bag is then heat sealed.

The sealed Freeze-dry Bag is transferred to a freeze-dryer which has a minimum shelf temperature of -70°C and a minimum condenser temperature of -85°C. The tissue is then frozen on the freeze-dryer shelf by ramping the shelf temperature at a rate of -2.5°C/minute to -35°C, and held for at least 10 minutes.

The drying cycle is such that the final residual moisture content of the sample is less than 6% and optimally 2%. In this example, the frozen dermis is dried by the following program:

1. The shelf temperature is ramped at a rate of -2.5°C/minute to -35°C, and held for 10 minutes, with vacuum set to 2000mT (266 Pa).
2. The shelf temperature is then ramped at a rate of 1.5°C/minute to -23°C, and held for 36 hours with vacuum set to 2000mT(266 Pa).
3. The temperature is then ramped at rate of 1.5°C/minute to a shelf temperature of -15°C, and held for 180 minutes with vacuum set to 2000mT(266 Pa).
4. The temperature is then ramped at a rate of 1.5°C/minute to a shelf temperature of -5°C and held for 180 minutes with vacuum set to 2000mT(266 Pa).

- 11 -

5. The temperature is finally ramped at a rate of 1.5°C/minute to a shelf temperature of 20°C and held for 180 minutes with the vacuum set to 0 mT(0 Pa).

Following drying, the Freeze-dry Bag containing the dried dermis is unloaded under an atmosphere of dry nitrogen gas, placed in a second predried impervious pouch and heat sealed under the same inert environment.

During the processing procedure and prior to sealing for freeze drying, a satellite sample is cut from the main sample and further processed under identical conditions to the main sample. Prior to use of the main sample in transplantation, all necessary quality assurance is performed on the satellite sample, including microbiology and structural analysis.

Following drying, the sample is stored at above freezing temperatures, optimally 4°C in a light protected environment.

Preparation Of Particulate Acellular Tissue Matrix

The following procedure utilizes AlloDerm®, an acellular tissue matrix packaged without a backing material the preparation of which is described above. AlloDerm® is commercially available from LifeCell Corporation, The Woodlands Texas. After removal from the packaging, the dry, acellular tissue matrix is cut into strips using a Zimmer mesher fitted with a non-interrupting "continuous" cutting wheel. The resulting long strips of acellular tissue matrix are cut into lengths of about 1 to about 2 centimeters in length.

A homogenizer and sterilized homogenizer probe, such as a LabTeck Macro homogenizer available from OMNI International, Warrenton VA, is assembled and cooled to cryogenic temperatures using sterile liquid nitrogen which is poured into the homogenizer tower. Once the homogenizer has reached cryogenic temperatures, acellular tissue matrix previously prepared into strips as noted above are added to the homogenizing tower containing sterile liquid nitrogen. The homogenizer is then activated so as to cryogenically fracture the strips of acellular tissue matrix. The time and duration of the cryogenic fractionation step will depend upon the homogenizer utilized, the size of the homogenizing chamber, the speed and time at which the homogenizer is operated and should be able to be determined by one of skill in the art by simple variation of the parameters to achieve the desired results.

The cryofractured particulate acellular tissue matrix material is sorted by particle size by washing the product of the homogenizer with liquid nitrogen through a series of metal screens,

- 12 -

that have also been cooled to liquid nitrogen temperatures. We have found it especially useful to utilize a combination of screens within the homogenizing tower of the type described above in which the particles are washed and sorted first to exclude oversized particles and then to exclude undersized particles.

5 Once isolated, the particulate acellular tissue matrix is removed and placed in a vial for freeze drying once the sterile liquid nitrogen has evaporated. This last step is to ensure that any residual moisture that may have been absorbed during the above procedure is removed.

10 The final product is a white powder having a particle size of about 1 micron to about 900 microns and preferably a particle size of about 30 microns to about 750 microns. Preferably the particles are distributed about a mean of about 150-300 microns. The material is readily rehydrated by suspension in normal saline or other similar suitable rehydrating agent. The rehydrated acellular tissue matrix may be resuspended in normal saline or any other suitable pharmaceutically compatible carrier.

15 Injection Of Particulate Acellular Tissue Matrix: A sample of the dry cryofractured particulate acellular tissue matrix made in accordance with the procedure disclosed hereinabove was rehydrated and resuspended in phosphate buffer saline at a concentration of about 50 mg of particulate material per milliliter of phosphate buffered saline. The suspension was drawn into 1 cc tuberculin syringes. The samples were sent by overnight delivery at 4° C to an independent laboratory for injection into test animals. The samples were injected either into the dorsum of
20 the back in the subcutaneous plane or subauricularly (on the back of the ears) of rats. The animals were monitored for 3 days, at which time samples of the skin surrounding and including the area of injection were excised for evaluation. Histological evaluation revealed particles of human dermis just above the subcutaneous muscle layer in the rat. Microscopic examination of the excised tissue revealed that the particulate acellular tissue matrix had been repopulated with
25 rat cells with no evidence of severe acute inflammatory response by the host animal.

30 Comparison Of Wet Processed And Cryofractured Acellular Tissue Matrix: Samples of both the wet processed (room temperature) particulate acellular tissue matrix and the cryofractured (liquid nitrogen temperature) particulate acellular tissue matrix were prepared in the following manner: Wet processed particulate acellular tissue matrix was made by first rehydrating a sample of AlloDerm® and cutting the rehydrated acellular tissue matrix into strips

- 13 -

and homogenizing those strips in phosphate buffered saline at room temperature. The cryofractured particulate acellular tissue matrix was prepared in accordance with the process of the present invention as described hereinabove. Prior to use, the cryofractured particulate acellular tissue matrix was rehydrated in phosphate buffered saline and pelleted using centrifugation.

Samples of each of the resulting particulate acellular tissue matrix materials were suspended in phosphate buffer saline at a concentration of about 50 mg of particulate material per milliliter of phosphate buffered saline. The suspension was drawn into 1 cc tuberculin syringes. The samples were sent by overnight delivery at 4° C to an independent laboratory for injection into test animals. Samples were injected either into the dorsum of the back in the subcutaneous plane or subauricularly into rats. The animals were monitored for 3 weeks after which samples of the tissue surrounding and including the point of injection were excised for evaluation. Macroscopic and microscopic inspection of the samples revealed the following:

	Wet Processed	Cryofractured
Macroscopic	1/15*	12/15*
Microscopic	6/30 *	24/30*

* # of samples exhibiting persistence of particulate AlloDerm® / Total # of samples

Upon review of the above, one of skill in the art should understand and appreciate that the samples that were processed in accordance with the present invention had a rate of persistence approximately four times that of the wet processed material. From this, such a person should conclude that the wet processed particulate acellular tissue matrix causes fundamental changes to the physiological properties of the acellular tissue matrix resulting in a more rapid degradation or resorption of the sample by the host animal.

Long Term Animal Study: Cryofractured particulate acellular porcine tissue matrix prepared in accordance with the process of the present invention was injected subcutaneously and subdermally in a pig model organism. A concentration of 150 mg of particulate matrix per milliliter of saline was used in this study. Biopsies from the injection sites were obtained at one, three and six months post-injection. These biopsies revealed evidence of persistence of the

- 14 -

particulate matrix at 6 months with no evidence of acute inflammation. Further, the particulate matrix had become repopulated with porcine fibroblasts and exhibited evidence of revascularization of the particulate matrix.

5 In view of the above disclosure, one of ordinary skill in the art should appreciate that one illustrative embodiment of the present invention includes a method of processing an acellular tissue matrix to give a particulate acellular tissue matrix, the method including: cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; and separating the resulting particles by size at cryogenic temperatures so as to produce the particulate acellular tissue matrix.

10 Another illustrative embodiment of the present invention includes a method of processing an acellular tissue matrix to give a particulate acellular tissue matrix. The illustrative the method includes: cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles of desired size to remove any moisture that may have been
15 absorbed so as to produce the particulate acellular tissue matrix.

Yet another illustrative embodiment of the present invention included a method of processing an acellular tissue matrix to give a particulate acellular tissue matrix, the method comprising: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size
20 at cryogenic temperatures; freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix; and rehydrating the dry particulate acellular tissue matrix.

In addition to the above methods, the present invention is also directed to the product of the processes described herein. In one illustrative embodiment the product includes the product
25 of the process disclosed herein along with growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogenic proteins, chondrocyte growth factor and combinations thereof. Another embodiment of the present invention includes the product of the present invention combined
30 with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells,

- 15 -

hematopoietic stem cells and combinations thereof. The product of the present invention may also further include analgesic drugs or hemostatic drugs or antibiotic drugs or combinations of these.

5 While the compositions and methods of this invention have been described in terms of preferred embodiments, it should be apparent to those of skill in the art that variations may be applied to the process described herein without departing from the concept and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are considered to be within scope and concept of the invention.

- 16 -

CLAIMS:

1. A method comprising processing an acellular tissue matrix so as to give an particulate tissue matrix.

2. The method of claim 1 wherein the particulate tissue matrix does not cause a significant foreign body response and substantial resorption of the tissue matrix in a mammal.

3. A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix, the method including:

cryofracturing the dry acellular tissue matrix at cryogenic temperatures; and
separating the resulting particles by size at cryogenic temperatures so as to produce the particulate acellular tissue matrix.

4. A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix, the method comprising:

cryofracturing the dry acellular tissue matrix at cryogenic temperatures;
separating the resulting particles by size at cryogenic temperatures; and
freeze drying the fraction of particles of desired size to remove any moisture that may have been absorbed so as to produce the particulate acellular tissue matrix.

5. A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix, the method comprising:

cutting sheets of dry acellular tissue matrix into strips;
cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures;
separating the resulting particles by size at cryogenic temperatures;
freeze drying the fraction of particles of desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix; and
rehydrating the dry particulate acellular tissue matrix.

6. The product of the process described in claims 1, 2, 3, 4 or 5.

7. The product of claim 7 further comprising growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogenic proteins, chondrocyte growth factor and combinations thereof.

- 17 -

8. The product of claim 7 further comprising stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
9. The product of claim 7 further comprising analgesic drugs.
- 5 10. The product of claim 7 further comprising hemostatic drugs.
11. The product of claim 7 further comprising antibiotic drugs.
12. The product of claim 7 wherein the dry particulate acellular tissue matrix has a particle size of about 1 microns to about 900 microns and preferably from about 30 microns to about 800 microns.
- 10 13. The method described in claims 1, 2, 3, 4 or 5 further comprising applying said particulate acellular tissue to a recipient site, said method of applying being selected from injecting, spraying, layering, packing, in-casing or combinations thereof.

1/2




FIG. 1

2/2




FIG. 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13861

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/19, 35/36; C08L 89/06

US CL : 424/422, 423, 426, 499; 514/21, 801; 523/T13, 309

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/422, 423, 426, 499; 514/21, 801; 523/113, 309

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P ---- Y,P	US 5,893,888 A (BELL) 13 April 1999, abstract, column 1, line 48 to column 3, line 22, and column 7, line 50 to column 8, line 27.	1-7, 12-13 ----- 1-13
X -- Y	US 5,695,998 A (BADYLAK et al.) 09 December 1997, abstract, column 2, lines 41-69, column 3, lines 12-24 and 45-69, column 5, lines 4-15 and 54-65 and column 6, lines 7-16.	1-12 ----- 1-12
X	US 5,275,826 A (BADYLAK et al.) 04 January 1994, abstract, column 2, lines 51-60, and example 3.	1-2, 4-7, 13
X -- Y	US 5,256,140 A (FALLICK) 26 October 1993, abstract and column lines 24-45.	1-6 ----- 1-6

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 AUGUST 1999

Date of mailing of the international search report

18 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ANDREW E. C. MERRIAM

Telephone No. (703) 308-2351

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/13861

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 4,776,173 A (KAMAREI et al.) 11 October 1988, abstract, column 3, line 15 to column 5, line 65 and examples 10-26.	1-6 ---- 1-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/13861

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS

search terms: tissue, xenogenic, autologous, allogenic, autogenic, skin, dermal, matrix, connective, collagen, elastin, acellular, extracellular, cryoground, cryofracture, lyophilize